Felder M, Wagenhäuser F J
Orthopade. 1986 Sep;15(5):379-87.
Osteoarthritis (OA) is one of the most common diseases requiring treatment. A clear clinical and pathophysiological understanding of the disease is required before treating a patient with OA. Drug therapy of patients with OA is mainly divided into two groups: a group receiving symptomatic therapy and a group receiving drugs intended to modify or improve the disease. Symptomatic therapy includes pure analgesics as well as non-steroidal antirheumatic drugs and muscle relaxants. Their use depends on the activity as well as on the form of clinical manifestation (activated/decompensated disease). If there are signs of severe activation, intra-articular steroids, orgotein or even synoviorthesis with yttrium are administered as local therapy. All of these therapies are used in the sense of trouble shooters, as they cannot alter the course of the disease in the long run. The disease-modifying substances have well been investigated in vitro and in animal models. Furthermore, some clinical trials have shown evidence for the usefulness of these substances in the therapy of OA.
骨关节炎（OA）是最常见的需要治疗的疾病之一。在治疗骨关节炎患者之前，需要对该疾病有清晰的临床和病理生理学认识。骨关节炎患者的药物治疗主要分为两组：一组接受对症治疗，另一组接受旨在改变或改善疾病的药物治疗。对症治疗包括单纯镇痛药以及非甾体类抗风湿药和肌肉松弛剂。它们的使用取决于疾病活动度以及临床表现形式（疾病活动期/失代偿期）。如果有严重活动的迹象，则将关节内注射类固醇、奥古蛋白甚至钇滑膜切除术作为局部治疗方法。所有这些治疗方法都是作为解决问题的手段使用的，因为从长远来看，它们无法改变疾病的进程。改善病情的药物已在体外和动物模型中进行了充分研究。此外，一些临床试验已证明这些药物在骨关节炎治疗中的有效性。
